

→ Eddy

Multiple Minor Histocompatibility Antigen Disparities Between a Recipient and Four HLA-Identical Potential Sibling Donors for Bone Marrow Transplantation

Erik A. F. Marijt, Willy F. J. Veenhof, Els Goulmy, Petra M. C. Kluck, Anneke Brand, Roel Willemze, Jon J. van Rood, and J. H. Fred Falkenburg

ABSTRACT: A patient with acute leukemia and her family including four HLA-identical siblings were analyzed to select a donor who was not only HLA- but also minor histocompatibility (mH) antigen compatible for allogeneic bone marrow transplantation (BMT). The HLA-A2 restricted mH antigen-specific HA-1, -2, -4, and -5 cytotoxic T-lymphocyte (CTL) clones were used to type the family members for expression of these mH antigens. The patient and one HLA-identical sibling were compatible for these mH antigens. This sibling was selected as the bone marrow donor. The patient engrafted promptly but developed acute and chronic graft-versus-host disease. To study the presence of other mH antigen disparities between recipient and donor, host-versus-graft CTL lines and clones were generated by stimulation of recipient peripheral blood lymphocytes (PBLs) with donor bone marrow cells, and graft-versus-host CTL lines were generated after BMT by stimulation of PBLs of donor origin with recipient bone marrow cells. These CTL lines were cytotoxic to cells from the bone marrow donor and

from the recipient, respectively, and to cells from several other family members. T-cell lines, generated from the patient after BMT by stimulation of recipient-derived PBLs with donor bone marrow cells, exhibited no specific cytotoxicity to donor or recipient cells. Chimerism studies after BMT revealed that the PBLs and T-cell lines generated after BMT were of donor origin. CTL lines that were generated from PBLs from the three other HLA-identical siblings in this family by stimulation with HLA-identical donor bone marrow cells also exhibited cytotoxicity to cells from several family members. Our results show that in addition to compatibility for HA-1, -2, -4, and -5 between the recipient and the donor, other mH antigen disparities existed between all HLA-identical siblings, illustrating the high degree of polymorphism of mH antigens and therefore the difficulty of finding mH antigen-compatible donor-recipient pairs even when more than one HLA-identical sibling is present within a family. *Human Immunology* 37, 221-228 (1993)

ABBREVIATIONS

aGvHD	acute graft-versus-host disease
BMMNC	bone marrow mononuclear cell
BMT	bone marrow transplantation
CTL	cytotoxic T lymphocyte
EBV	Epstein-Barr virus
GvH	graft versus host
HvG	host versus graft
IL-2	interleukin 2
LCL	lymphoblastoid cell line

Leuko-A	leukoagglutinin-A
mH	minor histocompatibility
MHC	major histocompatibility complex
PCR	polymerase chain reaction
PBL	peripheral blood lymphocyte
PHA	phytohemagglutinin
RFLP	restriction fragment-length polymorphism
TCGF	T-cell growth factor

From the Laboratory of Experimental Hematology (W A F M W F J V, P M C K, R W, J H F F) and the Department of Immunohematology and Bloodbank (W A F M E G A B J J v R), Leiden, The Netherlands

Address reprint requests to Dr W A F Marijt, Department of Hematology, Building 1, C2-R, University Medical Center, Rijnsburgerweg 10, 2333 AA Leiden, The Netherlands

Received (U) February 13 1993, accepted July 1 1993

INTRODUCTION

HLA-identical bone marrow transplantation (BMT) is frequently complicated by acute graft-versus-host disease (aGvHD). This complication is thought to be induced by donor T cells from the graft that specifically

TABLE 2 Reactivity of recipient derived α donor bone marrow CTL lines and clones

Effector cells	Specific lysis in ^{51}Cr release assay of IL 2 blasts from								
	Donor ac ^b	Rec ac	Sib 3 ac	Sib 4 ac	Sib 5 ac	Sib 6 ad	Sib 7 ad	Sib 8 bl	Mc hcr cl
CTL line 1 ^a	+++	-		+++	-		+++		
CTL line 1 A	+++	-	+++	+++	+++		+++		+++
CTL line 1 B	++		++	++	++	-			
Clone 10F8 ^d	+++	-	-	+++	-		+++		

^a Effector-target ratio 20:1

^b See Table 1 notes

See Table 1 notes

^d Effector-target ratio 5:1

clones with the same specificity CTL clone 10E8 is a representative example of these clones that recognized cells from the bone marrow donor and from siblings 4 and 7. Phenotypic analysis of the clones by FACS scanning, using anti-CD3, -CD4, and CD8 monoclonal antibodies (Becton-Dickinson, Mountain View CA USA) showed that they were CD3⁺CD8⁺. These results show that CTL lines can be generated with various mH antigen specificities from pre BMT recipient PBLs by stimulation with donor BMMNCs.

Recognition of cells from family members by GvH CTL lines Table 3 shows that the CTL lines generated from PBLs collected at several intervals after BMT and stimulated with irradiated recipient pretransplant BMMNCs differentially recognized cells from other family members, which suggested the presence of different mH antigen specificities in the GvH CTL lines.

Recognition of cells from family members by the sibling 3-4 and 5-antidonor CTL lines CTL lines were generated from PBLs from three other HLA identical siblings by stimulation with irradiated donor BMMNCs Table 4

shows that these CTL lines differentially recognized cells from other family members. CTL line 4-antidonor only lysed to a limited extent EBV LCLs from the donor but not IL 2 blasts.

Lack of donor specific recognition by post BMI antidonor bone marrow T cell lines To investigate the presence of residual potential donor directed CTLs in the peripheral blood of the recipient after BMT PBLs collected on days +14 +19 +27 +40 +60 and +180 were stimulated with irradiated donor BMMNCs. T cell lines generated from PBLs collected on days +14 +19 +27 and +40 were neither cytotoxic for cells from the recipient nor for cells from the bone marrow donor. Cytotoxicity against EBV LCLs but not IL 2 blasts from recipient and bone marrow donor were detected in the T cell lines generated from PBLs collected on days +60 and +180 and that had been stimulated with donor BMMNCs only. The observed cytotoxicity was not donor specific however since autologous cells also were recognized (data not shown). Determination of the origin of the T cell lines generated after BMT showed that they all were donor derived (Fig. 1).

TABLE 3 Reactivity of GvH CTL lines

Effector cells ^a	Specific lysis in ^{51}Cr release assay of IL 2 blasts from								
	Donor ac ^b	Rec ac	Sib 3 ac	Sib 4 ac	Sib 5 ac	Sib 6 ad	Sib 7 ad	Sib 8 bd	Mc hcr cl
CTL line +28	-	++	+++	+++	+++	+	+	++	+
CTL line +105	-	+	++			-		+	
CTL line +183	-	++	++	++			-	+	+
CTL line +365	-	++	+	+	-		-	+	

^a Effector-target ratio 20:1

^b See Table 1 notes

See Table 1 notes

TABLE 4 Reactivity of sibling 3, 4, and 5-antidonor CTL lines

Effector cells	Specific lysis in ⁵¹ Cr release assay of cells from											
	Donor		Rec		Sib 3		Sib 4		Sib 5		Mother	
	II 2 blasts ac	1BV LC1s ac	IL 2 blasts ac	1BV LC1s ac	II 2 blasts ac	II 2 blasts ac	II 2 blasts ac	II 2 blasts ad	II 2 blasts ad	II 2 blasts bd	II 2 blasts cd	
CTL line 3 α donor	+	+++		+++					+++	ND*	+++	+++
CTL line 4 α donor		+					-			ND		
CTL line 5 α donor	++	+++		+++	-			+		ND	++	

Effector:target ratio = 20:1

*See Table 1 notes

See Table 1 notes

†Not done

DISCUSSION


HLA-identical BMT may be complicated by severe aGvHD or graft rejection despite optimal matching for HLA class I and II antigens [1-7]. Both complications are thought to be the result of the recognition of mH antigens by immunocompetent T lymphocytes from donor or recipient origin, respectively [2-13]. Minor histocompatibility antigens are thought to be peptides derived from cellular proteins [26] that are bound in the groove of major histocompatibility complex (MHC) molecules. This MHC molecule-peptide complex can be recognized by alloreactive T lymphocytes [27]. Consequently, matching for mH antigens between donor

and recipient may decrease the incidence and severity of aGvHD and graft rejection.

In mice, more than 50 mH genes have been described [28]. In humans, several authors have described mH antigen-specific CTLs in patients after multiple blood transfusions and bone marrow and kidney transplantation [2, 29-32]. Mapping of the gene loci has been successful only for the male mH antigen H Y, both in humans and mice [33, 34], and for MTF, a mouse mH antigen encoded by mitochondrial DNA [35]. If the polymorphism of immunogenic human mH antigens is as extended as in mice, the chances of finding donor-recipient pairs identical for both major and minor histocompatibility antigens may be limited.

Previously, we have shown that, prior to BMT, recipient-antidonor cytotoxicity was demonstrated in seven of ten HLA-identical donor-recipient pairs [21]. In the present study, we show that although donor and recipient were matched for the mH antigens HA-1, -2, -4, and -5, additional cytotoxic reactivity against other, as yet undefined, mH antigens was present between these two siblings, both in the GvH and the HvG directions. The differences in recognition patterns between the HvG parent line and its sublines and between the GvH lines generated at different time intervals after BMT

FIGURE 1 RFLP analysis adapted for PCR amplification, of PBLs from the bone marrow donor and the recipient, and of the posttransplant antidonor bone marrow T cell lines. The *hinf*I represent PCR amplified DNA. *Hinf*I marked + are digested with the restriction enzyme *Hinf*I and tracks marked - are undigested. Tracks 1 and 2 are donor cell derived and produce only one band, whereas tracks 3 and 4 are recipient cell derived and produce two bands when digested with *Hinf*I (track 4). Recipient and donor cells were collected before BMT. Tracks 5-16 are derived from recipient post BMT antidonor BMMNC T cell lines, generated from recipient PBLs collected 14-180 days after BMT.



may reflect differences in the frequencies of the various mH antigen-specific CTL clones present in the CTL lines. The differential reactivity of the post-BMT GvH CTL lines may reflect *in vivo* sensitization of donor T cells against mH antigens. These mH antigens may be sequentially expressed on recipient stimulator cells, e.g., due to sequential infections by pathogens that up-regulate expression of various self-mH antigens. In addition, when PBLs from the three other HLA-identical siblings were stimulated with irradiated donor BMMNCs, CTL lines were generated that also recognized mH antigens expressed on cells from family members. These results illustrate multiple mH antigen disparities between the HLA-identical family members.

Despite the presence of host-antidonor cytotoxic reactivity prior to BMT, no graft rejection occurred. No residual recipient cells were demonstrated in peripheral blood and bone marrow collected from the recipient by chimerism studies after BMT. These findings were in accordance with the inability to generate recipient-antidonor CTL lines from posttransplant PBLs, suggesting that no functional alloreactive recipient T lymphocytes were present after BMT. These findings can be explained by the eradication of recipient-immunocompetent T cells by the conditioning regimen [36, 37], by their suppression by T cells from the graft [3], or by the posttransplant immunosuppressive therapy [38]. Uncomplicated engraftment despite *in vitro* HvG reactivity prior to BMT agrees with a previous report [21] in which we describe that, in seven of ten HLA-identical donor-recipient pairs, recipient-antidonor CTL lines were generated before BMT. None of these patients showed signs of graft failure or graft rejection.

GvHD was not prevented by matching for expression of the mH antigens HA-1, -2, -4, and -5, suggesting that also in the GvH direction additional mH antigen disparities were present between donor and recipient. Our *in vitro* results with T-cell lines, generated by stimulation of PBLs collected at several intervals after BMT with recipient pre-BMT BMMNCs, paralleled the *in vivo* observed GvH reactivity. Van Els *et al.* [39] could not demonstrate a clear correlation between the incidence of GvHD and the ability, or inability, to generate antihost CTL lines after BMT. Together the results reported here and those by Van Els *et al.* indicate that most donor-recipient pairs are mH antigen disparate, but that there is not necessarily a relation between the ability, or inability, to generate CTL lines that lyse recipient or donor cells and the occurrence of GvHD or graft rejection.

Presently, matching for mH antigens is not feasible due to their number and polymorphism. Quantitative, more than merely qualitative, differences in mH antigen-specific T-cell responses between recipients and

their potential donors may be correlated with graft rejection or GvHD. Quantitative differences may be estimated by using limiting dilution assays to determine CTL or T-helper-cell precursor frequencies as has been described in unrelated HLA-matched donor-recipient pairs or allogeneic responder-stimulator pairs by Kaminski *et al.* [40, 41] and Deacock *et al.* [42], respectively. Adapting these protocols to the specific situation of HLA-identical sibling BMT, e.g., by using BMMNCs as stimulator cells, may produce valuable information.

In conclusion, we have analyzed the mH antigen disparity between HLA-identical and -nonidentical family members of a patient with leukemia, and the possibility of finding a sibling bone marrow donor who was both HLA and mH antigen compatible. In addition to compatibility for the mH antigens HA-1, -2, -4, and -5 between bone marrow donor and recipient, disparity for multiple other mH antigens was demonstrated both in the HvG and the GvH directions. CTL lines were generated from PBLs from three other HLA-identical siblings by stimulation with donor BMMNCs, also recognizing mH antigens expressed on cells from family members. Donor-antirecipient, but no residual recipient-antidonor, reactivity was demonstrated at several intervals after BMT. In view of these findings, finding donor-recipient pairs that are HLA and mH antigen identical is unlikely. Quantitative, more than merely qualitative, differences in the immune responses to mH antigens between recipients and their potential donors may more likely determine the incidence or severity of GvHD or graft rejection following HLA-identical BMT.

ACKNOWLEDGMENTS

The authors thank Dr. M. Oudshoorn for the HLA-DP oligonucleotide typing. This study was supported in part by grants from the J. A. Cohen Institute for Radiopathology and Radiation Protection, J. H. T. Falkenburg is a Special Fellow of the Royal Netherlands Academy of Arts and Sciences.

REFERENCES

1. Goulmy E. Class I restricted human cytotoxic T lymphocytes directed against minor transplantation antigens and their possible role in organ transplantation. *Prog Allergy* 36:44, 1985.
2. Goulmy E. Minor histocompatibility antigens in man and their role in transplantation. *Transplant Rev* 2:29, 1988.
3. Martin PJ, Hansen JA, Storb R, Thomas ED. Human marrow transplantation: an immunological perspective. *Adv Immunol* 40:379, 1987.
4. Neudorf S, Filipovich A, Ramsay N, Kersey J. Prevention and treatment of acute graft versus host disease. *Semin Hematol* 21:91, 1984.

- 5 Martin PJ, Hanson JA, Torok Storb B, Dornum D, Preceptor D, O'Quigley J, Sanders J, Sullivan KM, Witherspoon RP, Decker HJ, Appelbaum P, Stewart P, Weisen P, Doney K, Buckner CD, Clift R, Storb R, Thomas GD. Effects of in vitro depletion of T cells in HLA identical allogeneic marrow grafts. *Bone Marrow Transplant* 3:445 (1988).
- 6 Kernan NA. Graft failure following transplantation of T cell depleted marrow. In Burakoff S, Dereg HJ, Ferrara JLM, Atkinson MK (eds). *Graft versus Host Disease: Research and Clinical Management*. New York: Marcel Dekker, 1989, p 557.
- 7 Mitsuhashi RT, Champlin RI, Gale RP, Ho WG, Lenarsky C, Winston D, Selch M, Flisshoff R, Giorgi JV, Wells J, Ferasiki P, Billing R, Feig S. Treatment of donor marrow with monoclonal anti-T antibody and complement for the prevention of graft versus host disease. *Ann Intern Med* 105:20 (1986).
- 8 Hale G, Cobbold S, Waldman H. T or Campath 1 users: T cell depletion with Campath 1 in allogeneic bone marrow transplantation. *Transplantation* 45:753 (1988).
- 9 Bordignon C, Kocover CA, Small IN, Flomenberg N, Dupont B, O'Reilly R, Kernan NA. Graft failure after T cell depleted HLA identical marrow transplants for leukemia II. In vitro analysis of host effector mechanisms. *Blood* 74:223 (1989).
- 10 Kernan NA, Flomenberg N, Dupont B, O'Reilly RJ. Graft rejection in recipients of T cell depleted HLA non identical marrow transplantation for leukemia. *Transplantation* 43:842 (1987).
- 11 Hsiehshuec K, Kernan NA, O'Reilly RJ, Dupont B, Yang SY. Bone marrow allograft rejection by T lymphocytes recognizing a single amino acid difference in HLA B41. *N Engl J Med* 323:1818 (1990).
- 12 Donohue J, Kernan NA. Characterization of cells emerging at the time of graft failure after BMT from an unrelated marrow donor. *Blood* 82:1023 (1993).
- 13 Voigt PJ, Gibbe WF, Marijt WAF, Goulmy I, Veenhof WJF, Hamilton MS, Brand A, Zwaan FL, Willemze R, Van Rood JJ, Falkenburg JHF. Rejection of a bone marrow graft by recipient derived cytotoxic T lymphocytes directed against minor histocompatibility antigens. *Lancet* 335:131 (1990).
- 14 Terasaki P, Bernoco D, Pir MS. Microdroplet testing for HLA A, B, C and D antigens. *Am J Clin Pathol* 69:103 (1978).
- 15 Yang SY. A standardized method for detection of HLA A and HLA B alleles by one dimensional isoelectric focusing (IEF) gel electrophoresis. In Dupont B (ed). *Histocompatibility Testing, 1987* (Immunobiology of HLA) vol 1. New York: Springer Verlag, 1987, p 332.
- 16 Bidwell JL, Bidwell FA, Laundry GJ, Klouda PT, Bradley BA. Allelotypes defined by short DQA and DQB cDNA probes correlate with and define splits of HLA DQ serological specificities. *Mol Immunol* 24:513 (1987).
- 17 Martelli M, Martelli A, Cohen D. HLA class II typing by the workshop defined RFLP specificities in unrelated individuals. In Dupont B (ed). *Histocompatibility Testing, 1987* (Immunology of HLA) vol 1. New York: Springer Verlag, 1987, p 943.
- 18 Van Els CACM, D'Amico J, Pool J, Blokland F, Bakker A, Van Elsen PJ, Van Rood JJ, Goulmy I. Immunogenetics of human minor histocompatibility antigens: their polymorphism and immunodominance. *Immunogenetics* 35:161 (1992).
- 19 Graff RJ, Bailey DW. The non H-2 histocompatibility loci and their antigens. *Transplant Rev* 15:16 (1973).
- 20 Rammensee H-G, Klein J. Polymorphism of minor histocompatibility genes in wild mice. *Immunogenetics* 17:637 (1983).
- 21 Marijt WAF, Veenhof WJF, Brand A, Goulmy I, Gibbe Willemze R, Van Rood JJ, Falkenburg JHF. Minor histocompatibility antigen specific cytotoxic T cell lines capable of lysing human hematopoietic progenitor cells can be generated in vitro by stimulation with HLA identical bone marrow cells. *J Exp Med* 173:101 (1991).
- 22 Van Rood JJ, Van Leeuwen A, Ploem JS. Simultaneous detection of two cell populations by two colour fluorescence and application to the recognition of B cell determinants. *Nature* 262:795 (1976).
- 23 Kimura A, Sasazuki T. Eleventh international histocompatibility workshop reference protocol for the HLA DNA typing technique. In Tsuji K, Aizawa M, Sasazuki T (eds). *HLA 1991 Proceedings of the 11th International Workshop and Conference Held in Yokohama, Japan 6-13 November 1991*. New York: Oxford University Press, 1992, p 397.
- 24 Goulmy E. HLA A, B restriction of cytotoxic T cells. In Ferrone S, Solheim BG (eds). *HLA Typing, Methodology and Clinical Aspects* vol 2. New York: CRC, 1982, p 105.
- 25 Gibbs PLM, Zielinsky R, Boyd C, Duguczyk A. Structure, polymorphism and novel repeated DNA elements revealed by a complete sequence of the human α -fetoprotein gene. *Biochemistry* 26:1332 (1987).
- 26 Wallby H, J, Rammensee H-G. Identification of classical minor histocompatibility antigens as cell derived peptide. *Nature* 343:275 (1990).
- 27 Loveland BF, Fischer Lindahl K. The definition and expression of minor histocompatibility antigens. In McCluskey J (ed). *Antigen Processing and Recognition*. London: CRC, 1991, p 173.
- 28 Wettstein PJ. Minor histocompatibility loci. In Litwin SD (ed). *Human Immunogenetics*. New York: Marcel Dekker, 1989, p 339.
- 29 Goulmy I, Termijtelen A, Bridley BA, Van Rood JJ. Y antigen killing by T cells of women is restricted by HLA. *Nature* 266:514 (1977).
- 30 Zier KS, Likins WL, Pierson GR, Leo MM. The use of cytotoxic T cell lines to detect the segregation of a human

- minor alloantigen within families *Hum Immunol* 7 117, 1983
- 31 Irie C, Beatty PG, Mickelson E, Thomas ED, Hansen JA. Alloreactive T cell responses between HLA-identical siblings: detection of anti-minor histocompatibility T cell clones induced in vivo. *Transplantation* 40 329, 1985
 - 32 Yaramoto J, Kariyone A, Akiyama N, Kano K, Takiguchi M. Presentation of human minor histocompatibility antigens by HLA-B35 and HLA-B38 molecules. *Proc Natl Acad Sci USA* 87 2583, 1990
 - 33 Simpson E, Chandler P, Goulmy E, Distèche CM, Ferguson-Smith MA, Page DC. Separation of the genetic loci for the H-Y antigen and for testis determination on human Y chromosome. *Nature* 326 876, 1987
 - 34 McLaren A, Simpson E, Epplen JT, Studer R, Koopman P, Evans EP, Burgoyne PS. Location of the genes controlling H-Y antigen expression and testis determination on the mouse Y chromosome. *Proc Natl Acad Sci USA* 85 6442, 1988
 - 35 Loveland B, Wang C-R, Yonekawa H, Hermel E, Fisher-Lindahl K. Maternally transmitted histocompatibility antigen of mice: a hydrophobic peptide of a mitochondrially encoded protein. *Cell* 60 971, 1990
 - 36 Champlin RE, Ho WG, Mitsuyasu R, Burnison M, Greenberg P, Holly G, Winston DW, Feig SA, Gale RP. Graft failure and leukemia relapse following T lymphocyte-depleted bone marrow transplantation: effects of intensification of immunosuppressive conditioning. *Transplant Proc* 19 2616, 1987
 - 37 Patterson J, Prentice HG, Brenner MK, Gilmore M, Janossy G, Ivory K, Skeggs D, Morgan H, Lord J, Blacklock HA, Hoffbrand AV, Apperley JF, Goldman JM, Burnett A, Gribben J, Alcorn M, Pearson C, McVickers I, Hann M, Reid C, Wardle D, Gravett PJ, Bacigalupo A, Robertson AG. Graft rejection following HLA matched T-lymphocyte depleted bone marrow transplantation. *Br J Hematol* 63 221, 1986
 - 38 Kernan NA, Bordignon C, Heller G, Cunningham I, Castro-Malaspina H, Shank B, Flomenburg N, Burns J, Yang SY, Black P, Collins N, O'Reilly RJ. Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia. I. Analysis of risk factors and results of secondary transplants. *Blood* 74 2227, 1989
 - 39 Van Els CACM, Bakker A, Zwinderman AH, Zwaan FE, Van Rood JJ, Goulmy E. Effector mechanisms in graft-versus-host disease in response to minor histocompatibility antigens. I. Absence of correlation with cytotoxic effector cells. *Transplantation* 50 62, 1990
 - 40 Kaminski E, Hows J, Man S, Brookes P, MacKinnon S, Hughes T, Avakian O, Goldman JM, Batchelor JR. Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation. *Transplantation* 48 608, 1989
 - 41 Kaminski E, Hows J, Goldman J, Batchelor RJ. Optimizing a limiting dilution culture system for quantitating frequencies of alloreactive cytotoxic T lymphocyte precursors. *Cell Immunol* 137 88, 1991
 - 42 Deacock S, Schwarzer A, Batchelor R, Goldman J, Lechler R. A rapid limiting dilution assay for measuring frequencies of alloreactive, interleukin-2-producing T cells in humans. *J Immunol Methods* 147 83, 1992